Bank of America Analysts Give Sanofi (EPA:SAN) a €100.00 Price Target

Bank of America set a €100.00 ($116.28) target price on Sanofi (EPA:SAN) in a report issued on Friday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other research firms also recently weighed in on SAN. Kepler Capital Markets set a €88.00 ($102.33) price target on shares of Sanofi and gave the stock a buy rating in a research note on Friday. Credit Suisse Group set a €82.00 ($95.35) price target on shares of Sanofi and gave the stock a buy rating in a research note on Tuesday, July 30th. Sanford C. Bernstein set a €95.00 ($110.47) price target on shares of Sanofi and gave the stock a buy rating in a research note on Tuesday, September 3rd. UBS Group set a €87.00 ($101.16) target price on shares of Sanofi and gave the company a buy rating in a research note on Wednesday, August 14th. Finally, JPMorgan Chase & Co. set a €81.00 ($94.19) target price on shares of Sanofi and gave the company a neutral rating in a research note on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of €87.27 ($101.47).

SAN opened at €79.09 ($91.97) on Friday. Sanofi has a fifty-two week low of €63.09 ($73.36) and a fifty-two week high of €92.97 ($108.10). The business’s fifty day simple moving average is €76.45.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: What are no-load funds?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.